Literature DB >> 19267370

Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II.

Ming-Hsi Wang1, Kathy J Helzlsouer, Michael W Smith, Judith A Hoffman-Bolton, Sandra L Clipp, Viktoriya Grinberg, Angelo M De Marzo, William B Isaacs, Charles G Drake, Yin Yao Shugart, Elizabeth A Platz.   

Abstract

BACKGROUND: Chronic intra-prostatic inflammation and obesity are thought to influence prostate carcinogenesis. Thus, variants in genes in these pathways could be associated with prostate cancer risk.
METHODS: We genotyped 17 common single nucleotide polymorphisms (SNPs) in RNASEL, TLR4, IL1B, IL6, IL8, IL10, TNF, CRP, ADIPOQ, LEP, PPARG, and TCF7L2 in 258 white prostate cancer cases and 258 matched controls nested in CLUE II. Single-locus analyses were conducted using conditional logistic regression. TagSNPs were selected in IL10, CRP, and TLR4 and haplotype analyses were done.
RESULTS: The A allele of IL10 -1082G>A (rs1800896), known to result in lower levels of this anti-inflammatory cytokine, was positively associated with risk (AG vs. GG, OR = 1.69, 95% CI: 1.10-2.60; AA vs. GG, OR = 1.81, 95% CI: 1.11-2.96; P (trend) = 0.02). Associations of IL10 haplotypes with prostate cancer were explained by high linkage disequilibrium between two tagSNPs (rs1800890 and rs3024496) and -1082G>A. A TLR4 candidate SNP (rs4986790; AG/GG vs. AA, OR = 0.60, 95% CI: 0.33-1.08; P(trend) = 0.09), known to have decreased expression and be associated with lower circulating levels of inflammatory mediators, and tagSNP (rs10116253; CC vs. TT, OR = 3.05, 95% CI: 1.11-8.41), but not haplotypes, were associated with risk. None of the other candidate SNPs or haplotypes was statistically significantly associated with risk.
CONCLUSION: Our prospective study suggests that genetic variation in IL10 and possibly TLR4 is associated with prostate cancer risk. Although none of the SNPs in the obesity genes tested was associated, this does not rule out a complex role of obesity and its metabolic consequences in prostate cancer etiology. . (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19267370      PMCID: PMC3016874          DOI: 10.1002/pros.20933

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  55 in total

1.  A meta-analysis of diabetes mellitus and the risk of prostate cancer.

Authors:  Jocelyn S Kasper; Edward Giovannucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

2.  C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.

Authors:  Claire Siemes; Loes E Visser; Jan-Willem W Coebergh; Ted A W Splinter; Jacqueline C M Witteman; André G Uitterlinden; Albert Hofman; Huibert A P Pols; Bruno H Ch Stricker
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

Review 3.  Obesity and prostate cancer: making sense out of apparently conflicting data.

Authors:  Stephen J Freedland; Elizabeth A Platz
Journal:  Epidemiol Rev       Date:  2007-05-03       Impact factor: 6.222

4.  RNASEL Arg462Gln polymorphism and prostate cancer in PLCO.

Authors:  Sarah E Daugherty; Richard B Hayes; Meredith Yeager; Gerald L Andriole; Nilanjan Chatterjee; Wen-Yi Huang; William B Isaacs; Elizabeth A Platz
Journal:  Prostate       Date:  2007-06-01       Impact factor: 4.104

Review 5.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

6.  Toll-like receptor 4 genetic variation and advanced prostate cancer risk.

Authors:  Iona Cheng; Sarah J Plummer; Graham Casey; John S Witte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-02       Impact factor: 4.254

7.  Association of IL-10 polymorphisms with prostate cancer risk and grade of disease.

Authors:  Jessica M Faupel-Badger; La Creis Renee Kidd; Demetrius Albanes; Jarmo Virtamo; Karen Woodson; Joseph A Tangrea
Journal:  Cancer Causes Control       Date:  2007-11-13       Impact factor: 2.506

Review 8.  Adipokines in obesity.

Authors:  Rexford S Ahima; Suzette Y Osei
Journal:  Front Horm Res       Date:  2008       Impact factor: 2.606

Review 9.  Obesity and prostate cancer: a role for adipokines.

Authors:  Tina Mistry; Janet E Digby; Ken M Desai; Harpal S Randeva
Journal:  Eur Urol       Date:  2007-03-26       Impact factor: 20.096

Review 10.  Obesity, metabolic syndrome, and prostate cancer.

Authors:  Ann W Hsing; Lori C Sakoda; Streamson Chua
Journal:  Am J Clin Nutr       Date:  2007-09       Impact factor: 7.045

View more
  73 in total

Review 1.  TLR4 polymorphisms and disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Ali A Shah; Sheeba Murad Mall; Shazia Choudhary; Tahir Hussain; Iltaf Ahmed; Syed Fazal Jalil; Muhammad Imran Raza
Journal:  Inflamm Res       Date:  2012-01-26       Impact factor: 4.575

2.  The IL-10 promoter haplotype and cancer risk: evidence from a meta-analysis.

Authors:  Kui Zhang; Lushun Zhang; Xianmin Wang; Lin Zhang
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

3.  A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II.

Authors:  Nrupen A Bhavsar; Jay H Bream; Alan K Meeker; Charles G Drake; Sarah B Peskoe; Djeneba Dabitao; Angelo M De Marzo; William B Isaacs; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-22       Impact factor: 4.254

4.  Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.

Authors:  Danyelle A Winchester; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Regina M Santella; Teresa L Johnson-Pais; Robin J Leach; Jianfeng Xu; S Lilly Zheng; Ian M Thompson; M Scott Lucia; Scott M Lippmann; Howard L Parnes; Paul J Dluzniewski; William B Isaacs; Angelo M De Marzo; Charles G Drake; Elizabeth A Platz
Journal:  Prostate       Date:  2015-06-05       Impact factor: 4.104

5.  The polymorphism interleukin-8 -251A/T is associated with a significantly increased risk of cancers from a meta-analysis.

Authors:  Ziliang Wang; Yang Liu; Lina Yang; Sheng Yin; Rongyu Zang; Gong Yang
Journal:  Tumour Biol       Date:  2014-04-24

6.  RNASEL Asp541Glu and Arg462Gln polymorphisms in prostate cancer risk: evidences from a meta-analysis.

Authors:  Bingbing Wei; Zhuoqun Xu; Jun Ruan; Ming Zhu; Ke Jin; Deqi Zhou; Zhiqiang Yan; Feng Xuan; Hongyi Zhou; Xing Huang; Jian Zhang; Peng Lu; Jianfeng Shao
Journal:  Mol Biol Rep       Date:  2011-06-09       Impact factor: 2.316

7.  Three adiponectin rs1501299G/T, rs822395A/C, and rs822396A/G polymorphisms and risk of cancer development: a meta-analysis.

Authors:  Hui-Jie Fan; Zheng-Fang Wen; Ben-Ling Xu; Jing-Jing Wu; Yong-Xu Jia; Ming Gao; Ming-Jun Li; Yan-Ru Qin
Journal:  Tumour Biol       Date:  2012-12-09

Review 8.  Cell type-specific regulation of IL-10 expression in inflammation and disease.

Authors:  Christian M Hedrich; Jay H Bream
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

9.  Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese.

Authors:  Jie Liu; Bao Song; Xueli Bai; Wenjian Liu; Zengjun Li; Jialin Wang; Yan Zheng; Zhehai Wang
Journal:  BMC Cancer       Date:  2010-08-24       Impact factor: 4.430

10.  Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans.

Authors:  J L Beebe-Dimmer; K A Zuhlke; A M Ray; E M Lange; K A Cooney
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-08-10       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.